You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRASmetastatic colorectal cancer: final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study)
|
|---|---|
| Published in |
BMC Cancer, November 2014
|
| DOI | 10.1186/1471-2407-14-865 |
| Pubmed ID | |
| Authors |
Julen Fernandez-Plana, Carlos Pericay, Guillermo Quintero, Vicente Alonso, Antonieta Salud, Miguel Mendez, Mercedes Salgado, Eugeni Saigi, Luis Cirera |
| Abstract |
This phase II study aims to evaluate the efficacy and safety of biweekly cetuximab in combination with oxaliplatin, leucovorin, and fluorouracil (FOLFOX-4) as first-line treatment of metastatic wild-type KRAS colorectal cancer. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 52 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 2% |
| Brazil | 1 | 2% |
| Unknown | 50 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 11 | 21% |
| Other | 7 | 13% |
| Student > Master | 6 | 12% |
| Student > Postgraduate | 4 | 8% |
| Student > Doctoral Student | 3 | 6% |
| Other | 9 | 17% |
| Unknown | 12 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 28 | 54% |
| Biochemistry, Genetics and Molecular Biology | 2 | 4% |
| Nursing and Health Professions | 2 | 4% |
| Materials Science | 2 | 4% |
| Chemistry | 2 | 4% |
| Other | 2 | 4% |
| Unknown | 14 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 February 2015.
All research outputs
#15,310,749
of 22,771,140 outputs
Outputs from BMC Cancer
#4,104
of 8,281 outputs
Outputs of similar age
#213,865
of 361,557 outputs
Outputs of similar age from BMC Cancer
#90
of 171 outputs
Altmetric has tracked 22,771,140 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,281 research outputs from this source. They receive a mean Attention Score of 4.3. This one is in the 40th percentile – i.e., 40% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 361,557 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 31st percentile – i.e., 31% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 171 others from the same source and published within six weeks on either side of this one. This one is in the 39th percentile – i.e., 39% of its contemporaries scored the same or lower than it.